European equities traded in the US as American depositary receipts were moving lower late Tuesday morning, declining 0.37% to 1,317.16 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Cellectis (CLLS), which climbed 14% and 4.6% respectively. They were followed by furniture maker Natuzzi (NTZ) and pharmaceutical company Novo Nordisk (NVO), which rose 4.1% and 1.8% respectively.
The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which fell 8.4% and 2.6% respectively. They were followed by petroleum refiner Equinor (EQNR) and medical device maker EDAP TMS (EDAP), which lost 2% each.
From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which increased 6% each. They were followed by biotech firm Autolus Therapeutics (AUTL) and cruise line operator Carnival (CUK), which were up 4.7% and 1.7% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and TC Biopharm (TCBP), which fell 10% and 5.9% respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Amarin (AMRN), which were down 4.8% and 2.5% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。